Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk Unveils New Manufacturing Facility In India
Novo Nordisk has inaugurated a new facility with a capacity of 26 million vials per annum in partnership with Torrent Pharmaceuticals. Jesper Hoiland, senior vice president of international
Novo Nordisk has inaugurated a new facility with a capacity of 26 million vials per annum in partnership with Torrent Pharmaceuticals. Jesper Hoiland, senior vice president of international
Torrent Pharma has announced its plans to invest in Dahej SEZ, India, reported Business Standard. The company is also eying the US from its facility in Dahej and
Addex has achieved statistically significant efficacy on the primary endpoint, increasing the number of symptom free days in the Phase IIb trial of ADX10059 as a monotherapy in
US subsidiary of Glenmark, Glenmark Generics has announced that it has settled all litigation pending between Glenmark and Medicis. The litigation were regarding the patent actions of Fluocinonide,
In one project, the National Human Genome Research Institute (NHGRI) will support work at ASU’s Biodesign Institute through a significant grant to boost research on rapid DNA sequencing
“We are very grateful and appreciative for ADDF’s support,” reported Dr. Joel Braunstein, managing member of C2N. “Beginning in 2008, ADDF provided funding to us at a vital
LyondellBasell Industries has launched Purell PE 3420F, a new low density polyethylene (LDPE) grade for use in pharmaceutical packaging. With a density of 0.933g/cm3, this product sets a
Schott has begun mass production of its Schott TopLyo pharmaceutical packaging for lyophilized (freeze-dried) drugs at its Muellheim, Germany facility. The Schott TopLyo packaging solution features a special
India-based Glenmark has entered into an exclusive license agreement with Medicis Pharmaceutical to co-develop and commercialise a specialty pharmaceutical product in North America. The product will be used
Simcere Pharmaceutical revenue increases to RMB 443.7m for the third quarter of 2009 compared to RMB 443.4m for the same period last year. Revenue from Endu amounted to